{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:04:20Z","timestamp":1783533860162,"version":"3.55.0"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,10,27]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background and objective<\/jats:title>\n                  <jats:p>Beta-blockers (BBs) decrease mortality and acute exacerbation (AE) rates in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular disease; however, information on their effects in patients with COPD and atrial fibrillation (AF) is limited. We aimed to assess the AE risk in patients with different severities of COPD and AF receiving BBs compared with that in patients receiving calcium channel blockers (CCBs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study used data from the Taiwan National Health Insurance Database from 2009 to 2018. Outcomes included AE-related emergency room visits and hospitalisation. HRs and 95% CIs were estimated using the Cox proportional hazards model. COPD severity was classified as mild or severe based on exacerbation history. Sensitivity analyses included treatment and subgroup analyses, and competing risk adjustment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After propensity score matching, 4486 pairs of BB and CCB users from 13\u2009462 eligible patients were included. The exacerbation risk for BB users was lower (HR 0.80; 95%\u2009CI 0.72 to 0.89) than that of CCB users. After stratification, BB benefits persisted in the mild COPD group (HR 0.75; 95%\u2009CI 0.66 to 0.85), unlike the severe COPD group (HR 0.95; 95%\u2009CI 0.75 to 1.20). The results of the subgroup analysis showed consistent protective effects even in patients without heart failure or myocardial infarction (adjusted HR 0.82; 95%\u2009CI 0.71 to 0.94).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We found that BB use in patients with mild COPD and AF was associated with a lower exacerbation risk than CCB use, and that close monitoring of BB use in patients with severe COPD and AF is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2023-001854","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:55:11Z","timestamp":1700528111000},"page":"e001854","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Beta-blockers reduce severe exacerbation in patients with mild chronic obstructive pulmonary disease with atrial fibrillation: a population-based cohort study"],"prefix":"10.1136","volume":"10","author":[{"given":"Shan-Ju","family":"Lin","sequence":"first","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Min","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan"},{"name":"Institute of clinical medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan"},{"name":"Health Outcome Research Center, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9258-3239","authenticated-orcid":false,"given":"Ching-Lan","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan"},{"name":"Health Outcome Research Center, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Pharmacy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"2025083110092422000_10.1.e001854.1","unstructured":"World Health Organization . The top 10 causes of death. 2020. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"2025083110092422000_10.1.e001854.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2025083110092422000_10.1.e001854.3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01261-2018","article-title":"What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement","volume":"52","author":"Kim","year":"2018","journal-title":"Eur Respir J"},{"key":"2025083110092422000_10.1.e001854.4","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.2147\/COPD.S318969","article-title":"Healthcare, medication utilization and outcomes of patients with COPD by GOLD classification in England","volume":"16","author":"Sansbury","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083110092422000_10.1.e001854.5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.hrtlng.2021.09.001","article-title":"A systematic literature review and meta-analysis on the impact of COPD on atrial fibrillation patient outcome","volume":"51","author":"Ye","year":"2022","journal-title":"Heart Lung"},{"key":"2025083110092422000_10.1.e001854.6","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1093\/eurheartj\/ehab453","article-title":"Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients","volume":"42","author":"Romiti","year":"2021","journal-title":"Eur Heart J"},{"key":"2025083110092422000_10.1.e001854.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"2025083110092422000_10.1.e001854.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000040"},{"key":"2025083110092422000_10.1.e001854.9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jfma.2016.10.005","article-title":"2016 guidelines of the Taiwan heart rhythm society and the Taiwan society of cardiology for the management of atrial fibrillation","volume":"115","author":"Chiang","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"2025083110092422000_10.1.e001854.10","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.hrthm.2018.06.044","article-title":"Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease","volume":"15","author":"You","year":"2018","journal-title":"Heart Rhythm"},{"key":"2025083110092422000_10.1.e001854.11","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","article-title":"Metoprolol for the prevention of acute exacerbations of COPD","volume":"381","author":"Dransfield","year":"2019","journal-title":"N Engl J Med"},{"key":"2025083110092422000_10.1.e001854.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa793"},{"key":"2025083110092422000_10.1.e001854.13","doi-asserted-by":"crossref","unstructured":"Karimi L , Lahousse L , De Nocker P , et al . Effect of \u0392-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam study. ERJ Open Res 2021;7. doi:10.1183\/23120541.00624-2020","DOI":"10.1183\/23120541.00624-2020"},{"key":"2025083110092422000_10.1.e001854.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2016.12.013"},{"key":"2025083110092422000_10.1.e001854.15","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S196293"},{"key":"2025083110092422000_10.1.e001854.16","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2147\/COPD.S174265","article-title":"Validity of Icd9-CM codes to diagnose chronic obstructive pulmonary disease from national health insurance claim data in Taiwan","volume":"13","author":"Ho","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083110092422000_10.1.e001854.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.11.036"},{"key":"2025083110092422000_10.1.e001854.18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/COPD.S284720","article-title":"Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the Association using joint Modelling","volume":"16","author":"Zhudenkov","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083110092422000_10.1.e001854.19","unstructured":"Global strategy for diagnosis management and prevention of COPD. 2023. Available: https:\/\/goldcopd.org\/2023-gold-report-2\/"},{"key":"2025083110092422000_10.1.e001854.20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0024"},{"key":"2025083110092422000_10.1.e001854.21","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2147\/COPD.S315151","article-title":"Beta-blockers in high-risk outpatients with chronic obstructive pulmonary disease are associated with all-cause mortality \u2013 the STATUETTE cohort study","volume":"16","author":"Damkj\u00e6r","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083110092422000_10.1.e001854.22","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.1.30"},{"key":"2025083110092422000_10.1.e001854.23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-2362.1999.00407.x","article-title":"Beta-blockers reduce the release and synthesis of Endothelin-1 in human endothelial cells","volume":"29","author":"Garlichs","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"2025083110092422000_10.1.e001854.24","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.2_Pt_1.301"},{"key":"2025083110092422000_10.1.e001854.25","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.supplement_2.13tac170"},{"key":"2025083110092422000_10.1.e001854.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2007.07.002"},{"key":"2025083110092422000_10.1.e001854.27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1513\/pats.200402-010MS","article-title":"Interactions between corticosteroids and Beta2-agonists in asthma and chronic obstructive pulmonary disease","volume":"1","author":"Johnson","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"2025083110092422000_10.1.e001854.28","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.101","article-title":"Functional desensitization of the \u0392 2 adrenoceptor is not dependent on agonist efficacy","volume":"3","author":"Rosethorne","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"2025083110092422000_10.1.e001854.29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020512","article-title":"\u0392-blockers reverse agonist-induced \u03922-AR downregulation regardless of their signaling profile","volume":"21","author":"Maccari","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025083110092422000_10.1.e001854.30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12890-018-0684-7","article-title":"Comorbidities and COPD severity in a clinic-based cohort","volume":"18","author":"Raherison","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2025083110092422000_10.1.e001854.31","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00215-2022","article-title":"Multidisciplinary care in chronic airway diseases: the Newcastle model","volume":"8","author":"McDonald","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025083110092422000_10.1.e001854.32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S2213-2600(22)00494-5","article-title":"GOLD COPD report: 2023 update","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025083110092422000_10.1.e001854.33","doi-asserted-by":"crossref","DOI":"10.1007\/s10038-006-0043-z","article-title":"Beta2-adrenergic receptor Polymorphisms are associated with asthma and COPD in adults","volume":"51","author":"Matheson","year":"2006","journal-title":"J Hum Genet"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-001854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:09:38Z","timestamp":1756660178000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-001854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,20]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bmjresp-2023-001854"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-001854","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}